🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the effort against drug-resistant strains of the infection, according to scientists.

A Global Health Concern

The sexually transmitted infection are on the rise worldwide, with figures suggesting in excess of 82 million infections per year. Particularly high rates are reported in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the context of growing infection rates, the spread of superbugs and the highly restricted available drugs currently available.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers hope that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in concurrent days. This treatment, which is employed against UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This authorization marks a significant shift in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin cured more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which involves a dual-drug approach. The study included hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in many regions with limited resources.

Medical professionals treating patients have expressed hope. The availability of a easy-to-administer therapy like this is seen as a "revolutionary step" for managing the epidemic. This is deemed vital to reduce the burden of the infection for people and to prevent the spread of extremely resistant gonorrhoea worldwide.